Michal Mark‐Danieli

Author

Michal Mark‐Danieli

Tel Aviv University

Also Known As

M Mark-Danieli, Michal Mark-Danieli, Michal Mark‐Danieli

Publications

373

Citations

H-Index

Concepts

All Affiliations

Tel Aviv University Edmond and Lily Safra Children's Hospital Sheba Medical Center Bar-Ilan University Hadassah Medical Center

About

Michal Mark‐Danieli is an author at Tel Aviv University specializing in medicine, tumor biology, and renal pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	227
2	Cell Biology	1	1	89
3	Immunology	1	1	96
4	Nephrology	1	1	42
5	Pathology	1	1	42

Michal Mark‐Danieli

Publications

371

Citations

H-Index

Page 1

	Year	Citations
Resistance or sensitivity of Wilms’ tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target Naomi Pode‐Shakked, Orit Harari‐Steinberg, Y. Haberman-Ziv, Oncogene Anti-fzd7 AntibodyMedicineImmunologyTumor ImmunityAnti-cancer Agent	2011	96
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets Naomi Pode‐Shakked, Rachel Shukrun, Michal Mark‐Danieli, EMBO Molecular Medicine Tumor BiologyUrologyXenotransplantationGenitourinary CancerKidney Research	2012	89
The Conserved Carboxy Terminus of the Capsid Domain of Human Immunodeficiency Virus Type 1 Gag Protein Is Important for Virion Assembly and Release Daniel R. Melamed, Michal Mark‐Danieli, Michal Kenan-Eichler, Journal of Virology	2004	62
Renal Hypodysplasia Associates with a Wnt4 Variant that Causes Aberrant Canonical Wnt Signaling Asaf Vivante, Michal Mark‐Danieli, Miriam Davidovits, Journal of the American Society of Nephrology GeneticsRenal PathologyGenetic EpidemiologyRenal InflammationPathology	2013	42
Single Point Mutations in the Zinc Finger Motifs of the Human Immunodeficiency Virus Type 1 Nucleocapsid Alter RNA Binding Specificities of the Gag Protein and Enhance Packaging and Infectivity Michal Mark‐Danieli, Nihay Laham-Karam, Michal Kenan-Eichler, Journal of Virology	2005	40
In Vivo Expansion of Cancer Stemness Affords Novel Cancer Stem Cell Targets: Malignant Rhabdoid Tumor as an Example Hana Golan, Rachel Shukrun, Revital Caspi, Stem Cell Reports	2018	30
NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target Rachel Shukrun, Hana Golan, Revital Caspi, Oncogenesis	2019	12

Page 1